ArticleOncoTargets and therapy2019

GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status.

Qiwen Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.